Recent Updates
Recently added Catalysts
GPCR Positive Sentiment Score: 70/100

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Key Takeaway: Structure Therapeutics Inc. announced its participation in two healthcare conferences in June 2026. The company, which focuses on developing oral small molecule therapeutics for metabolic diseases, particularly obesity, will provide live and archived webcasts accessible through its website. This initiative highlights its commitment to engaging with investors and promoting its innovative pipeline.
Price reaction · baseline $39.19 (2026-05-22 close) · hit after-hours · clean, no other GPCR news in the window
day 0 close · peak
+1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Structure Therapeutics is actively participating in investor conferences.
  • The company is focused on developing innovative treatments for obesity.
  • Their proprietary pipeline aims to address significant unmet medical needs.

Full Press Release Details

SAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in two upcoming healthcare conferences in June:
2026 Jefferies Global Healthcare Conference
Format: Fireside chat and 1x1 meetings
Date/time: Wednesday, June 3 at 12:15 p.m. ET
Location: New York, NY
Goldman Sachs 47thAnnual Global Healthcare Conference
Format: Fireside chat and 1x1 meetings
Date/time: Tuesday, June 9 at 10:00 a.m. ET
Location: Miami, FL
The live and archived webcasts will be accessible from the company’s website athttps://ir.structuretx.com/events-presentations/eventsand replays will be available for 90 days.
About Structure TherapeuticsStructure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visitwww.structuretx.com.

Investors:Corey Davis, Ph.D.LifeSci Advisors, LLC212-915-2577cdavis@lifesciadvisors.com

Jun YoonStructure Therapeutics Inc.ir@structuretx.com

Frequently Asked Questions

What is Structure Therapeutics focused on?

Structure Therapeutics focuses on developing oral small molecule therapeutics for metabolic diseases.

When will Structure Therapeutics participate in conferences?

Structure Therapeutics will participate in two healthcare conferences in June 2026.

How can investors access the conference webcasts?

Investors can access live and archived webcasts on the company's website.

What is the focus of Structure Therapeutics' pipeline?

The pipeline is focused on addressing obesity and other chronic metabolic conditions.

Last updated: May 26, 2026